Article
Medicine, General & Internal
Ausvydas Patasius, Giedre Smailyte
Summary: This study in Lithuania on prostate cancer screening revealed that before screening, patients who were not screened had higher all-cause mortality risk, while those who were screened had similar all-cause mortality risk to the general population. Additionally, screened patients with localized stage of disease had lower all-cause mortality risk compared to the general population.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Paul F. Pinsky, Howard Parnes
Summary: Screening for prostate cancer should take into consideration the risks and benefits. PSA screening can reduce prostate cancer deaths, but the reduction is small. Follow-up tests such as biopsy and MRI may be needed for individuals with elevated PSA levels. Patients with low-risk or favorable intermediate-risk prostate cancer may choose active surveillance over immediate curative treatment. Surgery and radiation therapy have good outcomes but can lead to complications.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Martin Eklund, Fredrik Jaderling, Andrea Discacciati, Martin Bergman, Magnus Annerstedt, Markus Aly, Axel Glaessgen, Stefan Carlsson, Henrik Groenberg, Tobias Nordstroem
Summary: In the context of organized prostate cancer screening, MRI with targeted and standard biopsy was shown to be noninferior to standard biopsy for detecting clinically significant prostate cancer, while also resulting in less detection of clinically insignificant cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Jonas Hugosson, Marianne Mansson, Jonas Wallstrom, Ulrika Axcrona, Sigrid V. Carlsson, Lars Egevad, Kjell Geterud, Ali Khatami, Kimia Kohestani, Carl-Gustaf Pihl, Andreas Socratous, Johan Stranne, Rebecka Arnsrud Godtman, Mikael Hellstrom
Summary: MRI-directed targeted biopsy for prostate cancer screening reduces the risk of overdiagnosis by half compared to systematic biopsy, but may delay the detection of intermediate-risk tumors in a small proportion of patients.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Urology & Nephrology
Maria Franlund, Marianne Mansson, Rebecka Arnsrud Godtman, Gunnar Aus, Erik Holmberg, Karin Stinesen Kollberg, Par Lodding, Carl-Gustaf Pihl, Johan Stranne, Hans Lilja, Jonas Hugosson
Summary: This study analyzed the results of the Goteborg randomized prostate cancer screening trial over 22 years and found that prostate specific antigen-based screening can significantly reduce prostate cancer mortality. However, not attending screening, starting after age 60, and stopping at age 70 may increase the risk of prostate cancer death.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Sigrid Carlsson, Rebecka Arnsrud Godtman, Carl-Gustav Pihl, Andrew Vickers, Hans Lilja, Jonas Hugosson, Marianne Mansson
Summary: This study aimed to investigate the relationship between the age at first prostate-specific antigen (PSA) screening and the reduction in prostate cancer mortality risk. The results showed that starting screening at a younger age was associated with a greater reduction in prostate cancer mortality risk. It is recommended that PSA screening should start no later than age 55.
Article
Medicine, General & Internal
Sandhya Kalavacherla, Paul Riviere, Juan Javier-DesLoges, Matthew P. Banegas, Rana R. McKay, James D. Murphy, Brent S. Rose
Summary: Despite the recommended age cutoff for PSA screening, older males in the US are still commonly overscreened for prostate cancer. Discussing the benefits of PSA testing with a clinician was associated with increased screening, highlighting the potential role of clinician-level interventions in reducing overscreening in older males.
Letter
Medicine, General & Internal
Kelvin Yan, Tao Ren
Summary: The author comments on an article discussing the use of Epstein-Barr virus DNA or antibodies as a biomarker for the diagnosis of nasopharyngeal carcinoma. They point out the high number needed to screen in order to detect a case of cancer and estimate the number needed to screen to prevent one death.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Plant Sciences
Yanhua Chen, Qianqian Zhou, Hong Zhang, Linfan Xu, Lianheng Lu, Bing Shu, Lihong Zhou, Fuwen Yuan
Summary: This study aims to explore the anti-tumor role and potential mechanism of Qingdai Decoction (QDT) on prostate cancer. The results showed that QDT can repress cancer growth in advanced prostate cancer models in an androgen receptor independent manner by targeting NOS3, TGFB1, and NCOA2.
JOURNAL OF ETHNOPHARMACOLOGY
(2023)
Article
Oncology
Michael V. Sherer, Edmund M. Qiao, Nikhil V. Kotha, Alexander S. Qian, Brent S. Rose
Summary: This study found that PSA screening was associated with reduced risk of prostate cancer-specific mortality (PCSM) among non-Hispanic Black men and non-Hispanic White men. Annual screening was particularly important for Black men.
Article
Oncology
Michael S. Leapman, Rong Wang, Henry Park, James B. Yu, Preston C. Sprenkle, Matthew R. Cooperberg, Cary P. Gross, Xiaomei Ma
Summary: The study evaluated the changes in PSA testing rates after the revisions in the USPSTF guideline on prostate cancer screening. It found that rates of PSA testing increased after the 2017 draft statement, especially among men aged 55 to 69 and 70 to 89 years.
Article
Oncology
Jianhui Qiu, Desheng Cai, Zixin Wang, Jingcheng Zhou, Yanqing Gong, Lin Cai, Kan Gong
Summary: The study found that GP 5 + 4 was associated with higher risks of all-cause mortality and cancer-specific mortality compared to GP 4 + 5 among patients with GS 9 prostate cancer.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Arla Vettenranta, Teemu J. Murtola, Jani Raitanen, Paavo Raittinen, Kirsi Talala, Kimmo Taari, Ulf-Hakan Stenman, Teuvo L. J. Tammela, Anssi Auvinen
Summary: Statin use affects the outcomes of PSA screening, with reduced incidence of advanced prostate cancer among statin users compared to nonusers, but similar detection rates for low-grade localized tumors.
Article
Oncology
Ville J. Vihervuori, Kirsi Talala, Kimmo Taari, Jorma Lahtela, Teuvo L. J. Tammela, Anssi Auvinen, Paavo Raittinen, Teemu J. Murtola
Summary: The study found that prostate cancer patients using antidiabetic medication, especially insulin and metformin users, had a higher risk of prostate cancer death. However, adjusting for blood glucose level abolished this risk increase, indicating that underlying diabetes is the main driver of the risk association.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2021)
Article
Public, Environmental & Occupational Health
Matthew T. Keys, Miquel Serra-Burriel, Natalia Martinez-Lizaga, Maria Pellise, Francesc Balaguer, Ariadna Sanchez, Enrique Bernal-Delgado, Antoni Castells
Summary: The study found that FIT-based organized colorectal cancer screening in Spain was associated with a reduction in population colorectal cancer mortality. No differences in outcome trends were observed between exposed and control provinces in the 7 years prior to screening implementation. Two years after implementation, exposed provinces experienced an increase in colorectal cancer incidence, followed by a decrease in mortality rates after 7 years.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
(2021)